Clinical Trial Update: Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update of panitumumab (Vectibix) for cutaneous squamous cell carcinoma; trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Drugs mentioned

• Vectibix (panitumumab)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Carcinoma, Squamous Cell | Phase 2 | Status: UNKNOWN